⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of CellCarta and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
CellCarta
↗Montreal, Canada
CellCarta is a global Contract Research Organization (CRO) specializing in precision medicine laboratory services for the biopharmaceutical industry. The company provides end-to-end sample measurement and custom testing solutions, with core expertise in immunology, histopathology, proteomics, genomics, and digital pathology/AI.
Formed through the 2019 fusion of Caprion Biosciences and HistoGeneX, CellCarta has expanded its capabilities through strategic acquisitions, including Reveal Biosciences and Clinical Logistics Inc. The company supports the entire drug development cycle, from discovery to late-stage clinical trials and companion diagnostic (CDx) development, operating facilities across North America, Europe, Australia, and China.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Ownership:private
Status:operating
FUNDING
Investors:Arsenal Capital Partners
PIPELINE
Stage:N/A
Modalities:Cell therapy, Antibody-drug conjugates (ADCs), RNA vaccines
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Reveal Biosciences, Clinical Logistics Inc., Mosaic Laboratories, Biogazelle
Key Partnerships:Lunit (AI-enabled digital pathology), Leica Biosystems (CDx development in China), Pillar Biosciences (Tumor profiling), Leinco Technologies (Proteomics/Antibodies), Slope (Biospecimen management)
COMPETITION
Position:Leader
Competitors:LabCorp, NeoGenomics, Tempus Labs, Altasciences
LEADERSHIP
Key Executives:
Martin LeBlanc - CEO
LINKS
Website:cellcarta.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with CellCarta. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.